ALUNBRIG® (brigatinib) Expert Opinion Video Series: Systemic efficacy of ALUNBRIG in patients with ALK+ aNSCLC
Professor Samreen Ahmed
Prescribing information is available at the top of the page.
Listen to Prof Samreen Ahmed review ALUNBRIG’s systemic efficacy from the ALTA-1L trial which compared first-line use of ALUNBRIG vs crizotinib in patients with ALK+ aNSCLC.
Using a real-world example from the ALTA-1L study, Prof Ahmed highlights the importance of ALUNBRIG as a first-line treatment option in improving symptoms of patients with ALK+ aNSCLC.
ALK, anaplastic lymphoma kinase; ALK+, ALK-positive; aNSCLC, advanced non-small cell lung cancer.
To enjoy the full experience of OncoConnect, including the ability to like and bookmark content for easy access via your account section, please register or login now.
